Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thyroid tablets versus levothyroxine after surgery for differentiated thyroid cancer
ChiCTR2200055714Phase 4Recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- Feb 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of thyroid, porcine and levothyroxine sodium in well-differentiated thyroid cancer (WDTC) and papillary thyroid cancer (PTC) (2 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Total clinical response rate at week 24. Started Feb 2022; status: recruiting.
02
Drugs
thyroid, porcinelevothyroxine sodium
03
Conditions
well-differentiated thyroid cancer (WDTC)papillary thyroid cancer (PTC)
Beyond the preview
Go deeper on ChiCTR2200055714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200055714.